What do you mean so? Does IMM have any commercial license for their IP in Ph1, Ph2 or even Ph3 and how has that stock pps reacted to clinical trial updates and market valuation of the stock as the IP are further developed???? The MC valuation for biotech start-up will increase based on clinical trial updates like it has always done for other stocks and IMU as the IP develop further then the market will value the stock accordingly with less volatility as the risk is minimise, I'm actually very surprise the pps has dropped to this low after the initial clinical trial update for VAXINIA released over 9 months ago as it not only demonstrated safety but efficacy was seen which usually is only seen in Ph2.
Why IMU is a multi multi bagger, page-25842
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |